Trial Profile
A RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF FOLFOX PLUS OR MINUS GDC-0449 IN PATIENTS WITH ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) CARCINOMA (NCI 8376)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.